{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:24:40Z","timestamp":1791401080251,"version":"4.3.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare malignancy derived from plasmacytoid dendritic cells, can mimic both acute leukemia and aggressive T-cell lymphoma. Therapy of this highly aggressive hematological disease should be initiated as soon as possible, especially in light of novel targeted therapies that have become available. However, differential diagnosis of BPDCN remains challenging. This retrospective study aimed to highlight the challenges to timely diagnoses of BPDCN. We documented the diagnostic and clinical features of 43 BPDCN patients diagnosed at five academic hospitals from 2001\u20132022. The frequency of BPDCN diagnosis compared to AML was 1:197 cases. The median interval from the first documented clinical manifestation to diagnosis of BPDCN was 3\u00a0months. Skin (65%) followed by bone marrow (51%) and blood (45%) involvement represented the most common sites. Immunophenotyping revealed CD4\u2009+\u2009, CD45\u2009+\u2009, CD56\u2009+\u2009, CD123\u2009+\u2009, HLA-DR\u2009+\u2009, and TCL-1\u2009+\u2009as the most common surface markers. Overall, 86% (e.g. CD33) and 83% (e.g., CD7) showed co-expression of myeloid and T-cell markers, respectively. In the median, we detected five genomic alterations per case including mutational subtypes typically involved in AML: DNA methylation (70%), signal transduction (46%), splicing factors (38%), chromatin modification (32%), transcription factors (32%), and RAS pathway (30%), respectively. The contribution of patients (30%) proceeding to any form of upfront stem cell transplantation (SCT; autologous or allogeneic) was almost equal resulting in beneficial overall survival rates in those undergoing allogeneic SCT (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0001). BPDCN is a rare and challenging entity sharing various typical characteristics of other hematological diseases. Comprehensive diagnostics should be initiated timely to ensure appropriate treatment strategies.\n                  <\/jats:p>","DOI":"10.1007\/s00277-023-05587-7","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T06:02:23Z","timestamp":1704780143000},"page":"1587-1599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations"],"prefix":"10.1007","volume":"103","author":[{"given":"Evgenii","family":"Shumilov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ghandili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"K\u00fcnstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Banz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Str\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Kolloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Beltraminelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kerkhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Legros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Feldmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"5587_CR1","unstructured":"Swerdlow SH HN, Facchetti F et al (2008) Blastic plasmacytoid dendritic cell neoplasm. In: WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press, pp 145\u20137"},{"key":"5587_CR2","unstructured":"NCCN clinical guidelines in oncology: myelodysplastic syndromes [Internet]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf. Accessed\u00a030 Sept 2023"},{"issue":"11","key":"5587_CR3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/ajh.25219","volume":"93","author":"F Fernandes","year":"2018","unstructured":"Fernandes F, Barreira R, Cortez J, Silveira M, Bain BJ (2018) The distinctive cytology and disease evolution of blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 93(11):1431\u20131432","journal-title":"Am J Hematol"},{"issue":"20","key":"5587_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"2","key":"5587_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F et al (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98(2):239\u2013246","journal-title":"Haematologica"},{"issue":"2","key":"5587_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.14146","volume":"174","author":"L Pagano","year":"2016","unstructured":"Pagano L, Valentini CG, Grammatico S, Pulsoni A (2016) Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol 174(2):188\u2013202","journal-title":"Br J Haematol"},{"issue":"19","key":"5587_CR7","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","volume":"4","author":"K Laribi","year":"2020","unstructured":"Laribi K, Baugier de Materre A, Sobh M, Cerroni L, Valentini CG, Aoki T et al (2020) Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv 4(19):4838\u201348","journal-title":"Blood Adv"},{"issue":"3","key":"5587_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjd.12412","volume":"169","author":"F Julia","year":"2013","unstructured":"Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L et al (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169(3):579\u2013586","journal-title":"Br J Dermatol"},{"issue":"9","key":"5587_CR9","doi-asserted-by":"publisher","first-page":"10174","DOI":"10.18632\/oncotarget.7101","volume":"7","author":"L Mart\u00edn-Mart\u00edn","year":"2016","unstructured":"Mart\u00edn-Mart\u00edn L, Almeida J, Pomares H, Gonz\u00e1lez-Barca E, Bravo P, Gim\u00e9nez T et al (2016) Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget 7(9):10174\u201310181","journal-title":"Oncotarget"},{"issue":"1","key":"5587_CR10","first-page":"2","volume":"166","author":"Z Feng","year":"2014","unstructured":"Feng Z, Zhou J, Bentley G (2014) Blastic plasmacytoid dendritic cell neoplasm: report of a case presenting with lung and central nervous system involvement and review of the literature. J Louisiana State Med Soc 166(1):2\u20139","journal-title":"J Louisiana State Med Soc"},{"issue":"23","key":"5587_CR11","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","volume":"125","author":"T Aoki","year":"2015","unstructured":"Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J et al (2015) Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood 125(23):3559\u20133562","journal-title":"Blood"},{"issue":"22","key":"5587_CR12","doi-asserted-by":"publisher","first-page":"19204","DOI":"10.18632\/oncotarget.4146","volume":"6","author":"L Mart\u00edn-Mart\u00edn","year":"2015","unstructured":"Mart\u00edn-Mart\u00edn L, L\u00f3pez A, Vidriales B, Caballero MD, Rodrigues AS, Ferreira SI et al (2015) Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget 6(22):19204\u201319216","journal-title":"Oncotarget"},{"issue":"1","key":"5587_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","volume":"57","author":"Q Bashir","year":"2022","unstructured":"Bashir Q, Milton DR, Popat UR et al (2022) Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51\u201356","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5587_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E et al (2013) Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for blood and marrow transplantation. Blood 121(3):440\u2013446","journal-title":"Blood"},{"issue":"5","key":"5587_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.14954","volume":"179","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Al Malki MM, Deotare U et al (2017) Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol 179(5):781\u2013789","journal-title":"Br J Haematol"},{"issue":"11","key":"5587_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.clml.2021.05.018","volume":"21","author":"NR Wilson","year":"2021","unstructured":"Wilson NR, Konopleva M, Khoury JD, Pemmaraju N (2021) Novel therapeutic approaches in blastic plasmacytoid dendritic cell neoplasm (BPDCN): era of targeted therapy. Clin Lymphoma Myeloma Leuk 21(11):734\u2013740","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"5587_CR17","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1177\/1078155220951850","volume":"27","author":"Y Samhouri","year":"2020","unstructured":"Samhouri Y, Ursu S, Dutton N, Tanvi V, Fazal S (2020) Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. J Oncol Pharm Pract 27(4):990\u2013995","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"5587_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00277-017-2947-4","volume":"96","author":"A Tzankov","year":"2017","unstructured":"Tzankov A, Hebeda K, Kremer M, Leguit R, Orazi A, van der Walt J et al (2017) Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol 96(5):765\u2013777","journal-title":"Ann Hematol"},{"issue":"3","key":"5587_CR19","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1182\/blood-2004-06-2416","volume":"105","author":"F Garnache-Ottou","year":"2005","unstructured":"Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E et al (2005) Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood 105(3):1256\u20131264","journal-title":"Blood"},{"issue":"5","key":"5587_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","volume":"145","author":"F Garnache-Ottou","year":"2009","unstructured":"Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E et al (2009) Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 145(5):624\u2013636","journal-title":"Br J Haematol"},{"issue":"2","key":"5587_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2133.2004.06296.x","volume":"152","author":"K Kawai","year":"2005","unstructured":"Kawai K (2005) CD56-negative blastic natural killer-cell lymphoma (agranular CD4(+)\/CD56(+) haematodermic neoplasm)? Br J Dermatol 152(2):369\u2013370","journal-title":"Br J Dermatol"},{"issue":"7","key":"5587_CR22","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1080\/10428194.2020.1737685","volume":"61","author":"F Guolo","year":"2020","unstructured":"Guolo F, Minetto P, Clavio M, Marcolin R, Miglino M, Passannante M et al (2020) Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. Leuk Lymphoma 61(7):1695\u20131701","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"5587_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/s41375-022-01538-9","volume":"36","author":"M Khanlari","year":"2022","unstructured":"Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S et al (2022) Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 36(5):1343\u20131350","journal-title":"Leukemia"},{"issue":"1","key":"5587_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/cyto.b.21761","volume":"98","author":"F Hamadeh","year":"2020","unstructured":"Hamadeh F, Awadallah A, Meyerson HJ, Beck RC (2020) Flow cytometry identifies a spectrum of maturation in myeloid neoplasms having plasmacytoid dendritic cell differentiation. Cytometry B Clin Cytom 98(1):43\u201351","journal-title":"Cytometry B Clin Cytom"},{"issue":"24","key":"5587_CR25","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","volume":"3","author":"F Garnache-Ottou","year":"2019","unstructured":"Garnache-Ottou F, Vidal C, Biichl\u00e9 S, Renosi F, Poret E, Pagadoy M et al (2019) How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv 3(24):4238\u20134251","journal-title":"Blood Adv"},{"issue":"4","key":"5587_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2013.283","volume":"28","author":"J Menezes","year":"2014","unstructured":"Menezes J, Acquadro F, Wiseman M, G\u00f3mez-L\u00f3pez G, Salgado RN, Talavera-Casa\u00f1as JG et al (2014) Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 28(4):823\u2013829","journal-title":"Leukemia"},{"issue":"15","key":"5587_CR27","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.18632\/oncotarget.2223","volume":"5","author":"A Stenzinger","year":"2014","unstructured":"Stenzinger A, Endris V, Pfarr N, Andrulis M, J\u00f6hrens K, Klauschen F et al (2014) Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget 5(15):6404\u20136413","journal-title":"Oncotarget"},{"issue":"3","key":"5587_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.hoc.2020.01.002","volume":"34","author":"MR Sapienza","year":"2020","unstructured":"Sapienza MR, Pileri S (2020) Molecular features of blastic plasmacytoid dendritic cell neoplasm: DNA mutations and epigenetics. Hematol Oncol Clin North Am 34(3):511\u2013521","journal-title":"Hematol Oncol Clin North Am"},{"issue":"23","key":"5587_CR29","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.3390\/cancers13235888","volume":"13","author":"CC Yin","year":"2021","unstructured":"Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W et al (2021) Integrated clinical genotype-phenotype characteristics of blastic plasmacytoid dendritic cell neoplasm. Cancers (Basel) 13(23):5888","journal-title":"Cancers (Basel)"},{"key":"5587_CR30","unstructured":"(EMA) EMA (2020) Approval of the marketing authorisation for Elzonris (tagraxofusp). https:\/\/www.emaeuropaeu\/en\/documents\/smop-initial\/questions-answers-approval-marketing-authorisation-elzonris-tagraxofusp_enpdf. Accessed\u00a030 Sept 2023"},{"issue":"9","key":"5587_CR31","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3390\/cancers14092287","volume":"14","author":"E B\u00f4le-Richard","year":"2022","unstructured":"B\u00f4le-Richard E, Pemmaraju N, Ca\u00ebl B, Daguindau E, Lane AA (2022) CD123 and more: how to target the cell surface of blastic plasmacytoid dendritic cell neoplasm. Cancers 14(9):2287","journal-title":"Cancers"},{"issue":"1","key":"5587_CR32","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","volume":"12","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S et al (2021) Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun 12(1):6436","journal-title":"Nat Commun"},{"issue":"3","key":"5587_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.hoc.2020.01.005","volume":"34","author":"D Hammond","year":"2020","unstructured":"Hammond D, Pemmaraju N (2020) Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Hematol Oncol Clin North Am 34(3):565\u2013574","journal-title":"Hematol Oncol Clin North Am"},{"issue":"13","key":"5587_CR34","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","volume":"110","author":"D Haase","year":"2007","unstructured":"Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110(13):4385\u20134395","journal-title":"Blood"},{"issue":"8","key":"5587_CR35","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood.V86.8.2906.2906","volume":"86","author":"D Haase","year":"1995","unstructured":"Haase D, Feuring-Buske M, K\u00f6nemann S, Fonatsch C, Troff C, Verbeek W et al (1995) Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 86(8):2906\u20132912","journal-title":"Blood"},{"issue":"8","key":"5587_CR36","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.leukres.2013.03.019","volume":"37","author":"F Braulke","year":"2013","unstructured":"Braulke F, Jung K, Schanz J, G\u00f6tze K, M\u00fcller-Thomas C, Platzbecker U et al (2013) Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. Leuk Res 37(8):900\u2013906","journal-title":"Leuk Res"},{"issue":"2","key":"5587_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1046\/j.1365-2141.1999.01559.x","volume":"106","author":"M Pfeilst\u00f6cker","year":"1999","unstructured":"Pfeilst\u00f6cker M, Reisner R, N\u00f6sslinger T, Gr\u00fcner H, Nowotny H, T\u00fcchler H et al (1999) Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 106(2):455\u2013463","journal-title":"Br J Haematol"},{"key":"5587_CR38","doi-asserted-by":"publisher","DOI":"10.1159\/isbn.978-3-318-05979-3","volume-title":"ISCN: an international system for human cytogenomic nomenclature (2016)","author":"J McGowan-Jordan","year":"2016","unstructured":"McGowan-Jordan J, Simons A, Schmid M (2016) ISCN: an international system for human cytogenomic nomenclature (2016). Karger, Basel"},{"issue":"1","key":"5587_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000353118","volume":"141","author":"A Simons","year":"2013","unstructured":"Simons A, Shaffer LG, Hastings RJ (2013) Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 edition. Cytogenet Genome Res 141(1):1\u20136","journal-title":"Cytogenet Genome Res"},{"issue":"6","key":"5587_CR40","doi-asserted-by":"publisher","first-page":"E152","DOI":"10.1002\/ajh.25089","volume":"93","author":"R Martin","year":"2018","unstructured":"Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F et al (2018) Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. Am J Hematol 93(6):E152\u2013E154","journal-title":"Am J Hematol"},{"issue":"7","key":"5587_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41408-022-00699-1","volume":"12","author":"A K\u00fcnstner","year":"2022","unstructured":"K\u00fcnstner A, Schwarting J, Witte HM, Bernard V, St\u00f6lting S, Kusch K et al (2022) Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm. Blood Cancer J 12(7):101","journal-title":"Blood Cancer J"},{"issue":"9","key":"5587_CR42","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/s41375-023-01968-z","volume":"37","author":"B Cuglievan","year":"2023","unstructured":"Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J et al (2023) Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767\u20131778","journal-title":"Leukemia"},{"issue":"4","key":"5587_CR43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","volume":"106","author":"W Wang","year":"2021","unstructured":"Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S et al (2021) Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica 106(4):1047\u20131055","journal-title":"Haematologica"},{"issue":"5","key":"5587_CR44","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","volume":"5","author":"F Renosi","year":"2021","unstructured":"Renosi F, Roggy A, Giguelay A, Soret L, Viailly P-J, Cheok M et al (2021) Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Adv 5(5):1540\u20131551","journal-title":"Blood Adv"},{"issue":"7","key":"5587_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41590-018-0136-9","volume":"19","author":"PF Rodrigues","year":"2018","unstructured":"Rodrigues PF, Alberti-Servera L, Eremin A, Grajales-Reyes GE, Ivanek R, Tussiwand R (2018) Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells. Nat Immunol 19(7):711\u2013722","journal-title":"Nat Immunol"},{"issue":"8","key":"5587_CR46","first-page":"2095","volume":"60","author":"MG Narducci","year":"2000","unstructured":"Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D et al (2000) Regulation of TCL1 expression in B- and T-Cell lymphomas and reactive lymphoid tissues1. Can Res 60(8):2095\u20132100","journal-title":"Can Res"},{"issue":"5","key":"5587_CR47","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","volume":"30","author":"M Ceribelli","year":"2016","unstructured":"Ceribelli M, Hou Zhiying E, Kelly Priscilla N, Da Huang W, Wright G, Ganapathi K et al (2016) A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell 30(5):764\u2013778","journal-title":"Cancer Cell"},{"issue":"2","key":"5587_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2013-05-500413","volume":"122","author":"L Boiocchi","year":"2013","unstructured":"Boiocchi L, Lonardi S, Vermi W, Fisogni S, Facchetti F (2013) BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. Blood 122(2):296\u2013297","journal-title":"Blood"},{"issue":"15","key":"5587_CR49","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.2021011817","volume":"138","author":"N Pemmaraju","year":"2021","unstructured":"Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S et al (2021) Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood 138(15):1373\u20131377","journal-title":"Blood"},{"issue":"9","key":"5587_CR50","doi-asserted-by":"publisher","first-page":"10174","DOI":"10.18632\/oncotarget.7101","volume":"7","author":"L Mart\u00edn-Mart\u00edn","year":"2016","unstructured":"Mart\u00edn-Mart\u00edn L, Almeida J, Pomares H et al (2016) Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget 7(9):10174\u201310181","journal-title":"Oncotarget"},{"issue":"8","key":"5587_CR51","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood.2019001144","volume":"134","author":"J Taylor","year":"2019","unstructured":"Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM et al (2019) Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood 134(8):678\u2013687","journal-title":"Blood"},{"issue":"5","key":"5587_CR52","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1309\/FY6PK436NBK0RYD4","volume":"127","author":"M Herling","year":"2007","unstructured":"Herling M, Jones D (2007) CD4+\/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 127(5):687\u2013700","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"5587_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11912-020-00921-y","volume":"22","author":"NJ Tsagarakis","year":"2020","unstructured":"Tsagarakis NJ, Paterakis G (2020) Dendritic cell leukemia: a review. Curr Oncol Rep 22(6):55","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"5587_CR54","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3324\/haematol.2018.202093","volume":"104","author":"S Maria Rosaria","year":"2019","unstructured":"Maria Rosaria S, Francesco A, Federica M, Stefania O, Fabio F, Maryam E et al (2019) Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica 104(4):729\u2013737","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"5587_CR55","doi-asserted-by":"publisher","first-page":"11496","DOI":"10.1182\/blood-2022-162212","volume":"140","author":"HM Witte","year":"2022","unstructured":"Witte HM, K\u00fcnstner A, Schwarting J, Bernard V, St\u00f6lting S, von Bubnoff N et al (2022) Genome-wide DNA methylation profiling in blastic plasmacytoid dendritic cell neoplasm. Blood 140(Supplement 1):11496\u201311497","journal-title":"Blood"},{"issue":"10","key":"5587_CR56","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood.2020007897","volume":"137","author":"W Xiao","year":"2021","unstructured":"Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF et al (2021) Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 137(10):1377\u20131391","journal-title":"Blood"},{"key":"5587_CR57","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1182\/blood-2018-99-119081","volume":"132","author":"W Xiao","year":"2018","unstructured":"Xiao W, Goldberg AD, Famulare C, Baik J, Gao Q, Tallman MS et al (2018) Acute myeloid leukemia with plasmacytoid dendritic cell differentiation: predominantly secondary AML, enriched for RUNX1 mutations, frequent cross-lineage antigen expression and poor prognosis. Blood 132:2789","journal-title":"Blood"},{"issue":"2","key":"5587_CR58","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","volume":"12","author":"K Togami","year":"2022","unstructured":"Togami K, Chung SS, Madan V, Booth CAG, Kenyon CM, Cabal-Hierro L et al (2022) Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov 12(2):522\u2013541","journal-title":"Cancer Discov"},{"issue":"7966","key":"5587_CR59","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-023-06156-8","volume":"618","author":"GK Griffin","year":"2023","unstructured":"Griffin GK, Booth CAG, Togami K, Chung SS, Ssozi D, Verga JA et al (2023) Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature 618(7966):834\u2013841","journal-title":"Nature"},{"issue":"11","key":"5587_CR60","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.3324\/haematol.2017.172742","volume":"102","author":"L Wang","year":"2017","unstructured":"Wang L, Yang M, Zhang X, Yang C, Huang X, Wang Z et al (2017) ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm. Haematologica 102(11):e470\u2013e472","journal-title":"Haematologica"},{"issue":"11","key":"5587_CR61","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.clml.2018.07.295","volume":"18","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Reljic T, Murthy HS, Ayala E, Kumar A (2018) Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 18(11):703\u20139.e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"5587_CR62","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1097\/HS9.0000000000000841","volume":"7","author":"L Pagano","year":"2023","unstructured":"Pagano L, Zinzani PL, Pileri S, Quaglino P, Cuglievan B, Berti E et al (2023) Unmet clinical needs and management recommendations for blastic plasmacytoid dendritic cell neoplasm: a consensus-based position paper from an ad hoc international expert panel. Hemasphere 7(3):e841","journal-title":"Hemasphere"},{"issue":"8","key":"5587_CR63","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/leu.2014.64","volume":"28","author":"MR Sapienza","year":"2014","unstructured":"Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA et al (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28(8):1606\u20131616","journal-title":"Leukemia"},{"issue":"2","key":"5587_CR64","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K et al (2017) Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov 7(2):156\u2013164","journal-title":"Cancer Discov"},{"issue":"2","key":"5587_CR65","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1002\/ajh.26417","volume":"97","author":"N Gangat","year":"2022","unstructured":"Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A et al (2022) Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 97(2):E62\u2013E67","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05587-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T02:03:49Z","timestamp":1712887429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05587-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5587"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05587-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Westphalia-Lippe Medical Association (no. 2023\u2013071-f-S); the Ethics Committee of the University Medical Center G\u00f6ttingen (no. 17\/4\/23 \u00dc); the Ethics Committee of the Hamburg Medical Association (no. 2022\u2013300263-BO-bet); and the Ethics Committee of the University L\u00fcbeck (no. 18\u2013311). Informed consent was obtained orally from the individual patient depicted in Fig.\u00a0\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}